Glioblastoma Multiforme Treatment Market Report by Drug Type (Temozolomide, Bevacizumab, Carmustine, Radiosensitizers, and Others), Route of Administration (Oral, Parenteral), Type of Molecule (Small Molecule, Biologics), Distribution Channel (Hospitals, Pharmacies, and Others), and Region 2025-2033

Glioblastoma Multiforme Treatment Market Report by Drug Type (Temozolomide, Bevacizumab, Carmustine, Radiosensitizers, and Others), Route of Administration (Oral, Parenteral), Type of Molecule (Small Molecule, Biologics), Distribution Channel (Hospitals, Pharmacies, and Others), and Region 2025-2033

Report Format: PDF+Excel | Report ID: SR112025A1488

Market Overview 2025-2033:

The global glioblastoma multiforme treatment market size reached USD 2.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 4.1 Billion by 2033, exhibiting a growth rate (CAGR) of 6.39% during 2025-2033. 

Report Attribute 
Key Statistics
Base Year
2024
Forecast Years
2025-2033
Historical Years
2019-2024
Market Size in 2024
USD 2.3 Billion
Market Forecast in 2033
USD 4.1 Billion
Market Growth Rate (2025-2033) 6.39%


Glioblastoma multiforme, also known as grade IV astrocytoma, is a malignant grade IV brain tumor that rapidly spreads within the brain cells and can also infect the nearby cells. Since it is characterized by rapid cell degeneration, it creates immense pressure on the brain resulting in severe headaches and seizures. Although the exact cause of the diseases is still unknown, several factors including rare hereditary disorders such as Turcot syndrome are believed to be its cause. It is one of the most lethal forms of brain cancer and is treatment-resistant in nature, wherein the patient has an extremely short survival period post-diagnosis. The current treatment procedure of the disease includes surgical resection, chemotherapy and radiation.

Increasing prevalence of oncological diseases and a growing geriatric population across the globe are among the key factors driving the market growth. Furthermore, the development of advanced treatment methods that counter the resistive properties of glioma stem cells is also positively influencing the market growth. Additionally, increasing research and development (R&D) activities in molecular biotechnology and gene therapy for cancer and related diseases have facilitated the development of various biological drugs. These drugs assist in diminishing the side-effects of the existing treatment methods, thus creating broader acceptance amongst patients. Moreover, initiatives undertaken by several governments across the globe to improve healthcare infrastructure, along with the rising awareness of the availability of various therapies, are further expected to create a positive outlook for the market. 

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global glioblastoma multiforme treatment market report, along with forecasts at the global and regional level from 2025-2033. Our report has categorized the market based on drug type, route of administration, type of molecule, and distribution channel.

Breakup by Drug Type:

  • Temozolomide 
  • Bevacizumab
  • Carmustine
  • Radiosensitizers
  • Others
     

Breakup by Route of Administration:

  • Oral
  • Parenteral
     

Breakup by Type of Molecule:

  • Small Molecule
  • Biologics
     

Breakup by Distribution Channel:

  • Hospitals
  • Pharmacies
  • Others
     

Breakup by Region:

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America
     

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Sun Pharmaceutical Industries, Celldex Therapeutics, Pfizer, F. Hoffmann La Roche, Bristol-Myers Squibb, Teva Pharmaceuticals, Exelixis, Angiochem and Arbor Pharmaceuticals.

IMARC Group’s latest report provides a deep insight into the global glioblastoma multiforme treatment market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the glioblastoma multiforme treatment market in any manner.

Report Coverage:

Report Features Details
Base Year of the Analysis 2024
Historical Period 2019-2024
Forecast Period 2025-2033
Units Billion USD
Segment Coverage Drug Type, Route of Administration, Type of Molecule, Distribution Channel, Region
Region Covered Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Companies Covered Sun Pharmaceutical Industries, Celldex Therapeutics, Pfizer, F. Hoffmann La Roche, Bristol-Myers Squibb, Teva Pharmaceuticals, Exelixis, Angiochem and Arbor Pharmaceuticals
Customization Scope 10% Free Customization
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Key Questions Answered in This Report

The global glioblastoma multiforme treatment market was valued at USD 2.3 Billion in 2024.

We expect the global glioblastoma multiforme treatment market to exhibit a CAGR of 6.39% during 2025-2033

The rising prevalence of oncological diseases, along with the growing consumer awareness towards the availability of numerous therapies for glioblastoma multiforme treatment, is primarily driving the global glioblastoma multiforme treatment market.

The sudden outbreak of the COVID-19 pandemic had led to the postponement of various elective glioblastoma multiforme treatment procedures across several nations to reduce the risk of the coronavirus infection upon hospital visits or interaction with healthcare professionals and medical equipment.

Based on the route of administration, the global glioblastoma multiforme treatment market can be categorized into oral and parenteral. Currently, oral accounts for the majority of the global market share.

Based on the type of molecule, the global glioblastoma multiforme treatment market has been segregated into small molecule and biologics, where small molecule currently exhibits a clear dominance in the market.

Based on the distribution channel, the global glioblastoma multiforme treatment market can be bifurcated into hospitals, pharmacies, and others. Currently, hospitals hold the largest market share.

On a regional level, the market has been classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America, where North America currently dominates the global market.

Some of the major players in the global glioblastoma multiforme treatment market include Sun Pharmaceutical Industries, Celldex Therapeutics, Pfizer, F. Hoffmann La Roche, Bristol-Myers Squibb, Teva Pharmaceuticals, Exelixis, Angiochem, and Arbor Pharmaceuticals.

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Glioblastoma Multiforme Treatment Market Report by Drug Type (Temozolomide, Bevacizumab, Carmustine, Radiosensitizers, and Others), Route of Administration (Oral, Parenteral), Type of Molecule (Small Molecule, Biologics), Distribution Channel (Hospitals, Pharmacies, and Others), and Region 2025-2033
Purchase Options New Year Sale
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials